Novocure surges as cancer therapy succeeds in late-stage trial

NovoCure

27/03/2024 11:52

** Shares of Novocure  NVCR.O  rise ~31.5% to $17.19
premarket
    ** Co says its cancer therapy met the main goal of slowing
progression of the disease in patients with non-small cell lung
cancer (NSCLC)
    ** Says the therapy, along with supportive care, slowed the
spread of cancer to the brain to 21.9 months compared to 11.3
months from supportive care alone
    ** NSCLC is the most common type of lung cancer, and kills
more people in the United States than any other form of cancer
    ** Up to last close, stock down 77.6% in the last 12 months

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))